Legal & General Group’s Karyopharm Therapeutics KPTI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-916
| Closed | -$20.7K | – | 3467 |
|
|
2024
Q1 | $20.7K | Hold |
916
| – | – | ﹤0.01% | 2947 |
|
|
2023
Q4 | $11.9K | Hold |
916
| – | – | ﹤0.01% | 3199 |
|
|
2023
Q3 | $18.4K | Sell |
916
-5,303
| -85% | -$119K | ﹤0.01% | 3067 |
|
|
2023
Q2 | $167K | Buy |
6,219
+2,985
| +92% | +$129K | ﹤0.01% | 2772 |
|
|
2023
Q1 | $189K | Buy |
3,234
+179
| +6% | +$8.84K | ﹤0.01% | 2608 |
|
|
2022
Q4 | $156K | Buy |
3,055
+534
| +21% | +$37K | ﹤0.01% | 2700 |
|
|
2022
Q3 | $207K | Buy |
2,521
+283
| +13% | +$21.1K | ﹤0.01% | 2617 |
|
|
2022
Q2 | $151K | Buy |
2,238
+115
| +5% | +$10.5K | ﹤0.01% | 2736 |
|
|
2022
Q1 | $234K | Hold |
2,123
| – | – | ﹤0.01% | 2616 |
|
|
2021
Q4 | $205K | Buy |
2,123
+120
| +6% | +$12K | ﹤0.01% | 2716 |
|
|
2021
Q3 | $175K | Buy |
2,003
+781
| +64% | +$81.1K | ﹤0.01% | 2727 |
|
|
2021
Q2 | $190K | Sell |
1,222
-56
| -4% | -$8.13K | ﹤0.01% | 2545 |
|
|
2021
Q1 | $202K | Buy |
1,278
+12
| +0.9% | +$2.53K | ﹤0.01% | 2454 |
|
|
2020
Q4 | $294K | Sell |
1,266
-8
| -0.6% | -$1.85K | ﹤0.01% | 2350 |
|
|
2020
Q3 | $279K | Sell |
1,274
-205
| -14% | -$50.1K | ﹤0.01% | 2303 |
|
|
2020
Q2 | $420K | Buy |
1,479
+598
| +68% | +$177K | ﹤0.01% | 2209 |
|
|
2020
Q1 | $254K | Sell |
881
-186
| -17% | -$51.3K | ﹤0.01% | 2233 |
|
|
2019
Q4 | $306K | Buy |
1,067
+183
| +21% | +$39.7K | ﹤0.01% | 2312 |
|
|
2019
Q3 | $128K | Buy |
884
+94
| +12% | +$12.7K | ﹤0.01% | 2453 |
|
|
2019
Q2 | $71K | Buy |
790
+116
| +17% | +$9.31K | ﹤0.01% | 2649 |
|
|
2019
Q1 | $59K | Hold |
674
| – | – | ﹤0.01% | 2652 |
|
|
2018
Q4 | $95K | Buy |
674
+160
| +31% | +$27K | ﹤0.01% | 2476 |
|
|
2018
Q3 | $131K | Hold |
514
| – | – | ﹤0.01% | 2434 |
|
|
2018
Q2 | $131K | Buy |
514
+86
| +20% | +$21.3K | ﹤0.01% | 2412 |
|
|
2018
Q1 | $86K | Sell |
428
-193
| -31% | -$38.5K | ﹤0.01% | 2517 |
|
|
2017
Q4 | $90K | Hold |
621
| – | – | ﹤0.01% | 2631 |
|
|
2017
Q3 | $102K | Buy |
621
+88
| +17% | +$12.6K | ﹤0.01% | 2636 |
|
|
2017
Q2 | $73K | Buy |
533
+79
| +17% | +$11.7K | ﹤0.01% | 2773 |
|
|
2017
Q1 | $88K | Sell |
454
-44
| -9% | -$7.06K | ﹤0.01% | 2610 |
|
|
2016
Q4 | $70K | Buy |
498
+201
| +68% | +$27.2K | ﹤0.01% | 2754 |
|
|
2016
Q3 | $43K | Hold |
297
| – | – | ﹤0.01% | 2597 |
|
|
2016
Q2 | $31K | Buy |
297
+134
| +82% | +$17.4K | ﹤0.01% | 2719 |
|
|
2016
Q1 | $21K | Hold |
163
| – | – | ﹤0.01% | 2663 |
|
|
2015
Q4 | $33K | Hold |
163
| – | – | ﹤0.01% | 2612 |
|
|
2015
Q3 | $26K | Hold |
163
| – | – | ﹤0.01% | 2676 |
|
|
2015
Q2 | $63K | Hold |
163
| – | – | ﹤0.01% | 2428 |
|
|
2015
Q1 | $75K | Hold |
163
| – | – | ﹤0.01% | 2229 |
|
|
2014
Q4 | $90K | Hold |
163
| – | – | ﹤0.01% | 2063 |
|
|
2014
Q3 | $90K | Buy |
+163
| New | +$92K | ﹤0.01% | 1957 |
|
Other funds holding KPTI
PAI
EP
Legal & General Group's KPTI Position: Q2 2024 in Review
Legal & General Group sold out of Karyopharm Therapeutics (KPTI) in Q2 2024, closing a stake of 916 shares — an estimated $20.7K sold.
Legal & General Group first reported a position in KPTI in Q3 2014 and held it in 39 quarters. The position peaked at $420K in Q2 2020. 114 funds tracked by Wall St. Rank hold KPTI as of Q2 2024.
- Legal & General Group reported no remaining Karyopharm Therapeutics position as of Q2 2024 after selling out during the quarter.
- Legal & General Group sold 916 Karyopharm Therapeutics shares in Q2 2024, an estimated $20.7K.
- Legal & General Group first reported a position in Karyopharm Therapeutics in Q3 2014 and held it in 39 quarters.
- Legal & General Group's Karyopharm Therapeutics position peaked at $420K in Q2 2020.
- 114 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2024.
Based on Legal & General Group's 13F filing for Q2 2024, filed 14 Aug 2024.